ArticleFrontiers in public health2023

Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04.

Mei Zhan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.